Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study
Само за регистроване кориснике
2015
Аутори
Kovač, MirjanaKovac, Zeljko
Tomasević, Zorica
Vucicević, Slavko
Đorđević, Valentina
Pruner, Iva
Radojković, Dragica
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism(VTE) in breast cancer patients range from 2.4 to 7.1. The occurrence of thrombosis in patients with breast cancer complicates the clinical condition and causes a change of treatment. Our study was conducted in order to investigate the influence of patient-related risk factors for thrombosis development in breast cancer patients whose treatment included adjuvant tamoxifen. Methods: The prospective, single center, case control study included 150 breast cancer women, 50 whom developed venous thrombosis during adjuvant tamoxifen and 100 whom did not have thrombosis, as a control group. Patient-related risk factors such as: age, body mass index, previous VTE, varicose veins, concomitant diseases, the presence of prothrombotic mutations (FV Leiden, FII G20210A) and FVIII activity were evaluated in both groups. Results: In respect of prothrombotic mutations, the FV Leiden mutation was present in a higher nu...mber of women from the VTE group (10/50 vs 7/100; P = 0.020). Additionally, FVIII activity was significantly higher in the VTE group; median (IQR), of 1.79 (0.69) vs 1.45 (0.55); P lt 0.001 and more women in this group (24/50 vs 34/100) had increased FVIII activity; P = 0.020. In those women with FVIII gt 1.5 IU/ml, who were carriers of prothrombotic mutations, an OR of 3.76 (CI 95% 1.276-11.096; P = 0.016) was obtained for VTE. Conclusion: The results of our study showed that the factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen.
Кључне речи:
Venous thromboembolism / Tamoxifen / FV Leiden / Factor VIII / Breast cancerИзвор:
European Journal of Internal Medicine, 2015, 26, 1, 63-67Издавач:
- Elsevier, Amsterdam
Финансирање / пројекти:
- Комплексне болести као модел систем за проучавање модулације фенотипа-структурна и функционална анализа молекуларних биомаркера (RS-MESTD-Basic Research (BR or ON)-173008)
DOI: 10.1016/j.ejim.2014.12.015
ISSN: 0953-6205
PubMed: 25592075
WoS: 000348503100012
Scopus: 2-s2.0-84921550543
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Kovač, Mirjana AU - Kovac, Zeljko AU - Tomasević, Zorica AU - Vucicević, Slavko AU - Đorđević, Valentina AU - Pruner, Iva AU - Radojković, Dragica PY - 2015 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/852 AB - Background: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism(VTE) in breast cancer patients range from 2.4 to 7.1. The occurrence of thrombosis in patients with breast cancer complicates the clinical condition and causes a change of treatment. Our study was conducted in order to investigate the influence of patient-related risk factors for thrombosis development in breast cancer patients whose treatment included adjuvant tamoxifen. Methods: The prospective, single center, case control study included 150 breast cancer women, 50 whom developed venous thrombosis during adjuvant tamoxifen and 100 whom did not have thrombosis, as a control group. Patient-related risk factors such as: age, body mass index, previous VTE, varicose veins, concomitant diseases, the presence of prothrombotic mutations (FV Leiden, FII G20210A) and FVIII activity were evaluated in both groups. Results: In respect of prothrombotic mutations, the FV Leiden mutation was present in a higher number of women from the VTE group (10/50 vs 7/100; P = 0.020). Additionally, FVIII activity was significantly higher in the VTE group; median (IQR), of 1.79 (0.69) vs 1.45 (0.55); P lt 0.001 and more women in this group (24/50 vs 34/100) had increased FVIII activity; P = 0.020. In those women with FVIII gt 1.5 IU/ml, who were carriers of prothrombotic mutations, an OR of 3.76 (CI 95% 1.276-11.096; P = 0.016) was obtained for VTE. Conclusion: The results of our study showed that the factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen. PB - Elsevier, Amsterdam T2 - European Journal of Internal Medicine T1 - Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study EP - 67 IS - 1 SP - 63 VL - 26 DO - 10.1016/j.ejim.2014.12.015 ER -
@article{ author = "Kovač, Mirjana and Kovac, Zeljko and Tomasević, Zorica and Vucicević, Slavko and Đorđević, Valentina and Pruner, Iva and Radojković, Dragica", year = "2015", abstract = "Background: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism(VTE) in breast cancer patients range from 2.4 to 7.1. The occurrence of thrombosis in patients with breast cancer complicates the clinical condition and causes a change of treatment. Our study was conducted in order to investigate the influence of patient-related risk factors for thrombosis development in breast cancer patients whose treatment included adjuvant tamoxifen. Methods: The prospective, single center, case control study included 150 breast cancer women, 50 whom developed venous thrombosis during adjuvant tamoxifen and 100 whom did not have thrombosis, as a control group. Patient-related risk factors such as: age, body mass index, previous VTE, varicose veins, concomitant diseases, the presence of prothrombotic mutations (FV Leiden, FII G20210A) and FVIII activity were evaluated in both groups. Results: In respect of prothrombotic mutations, the FV Leiden mutation was present in a higher number of women from the VTE group (10/50 vs 7/100; P = 0.020). Additionally, FVIII activity was significantly higher in the VTE group; median (IQR), of 1.79 (0.69) vs 1.45 (0.55); P lt 0.001 and more women in this group (24/50 vs 34/100) had increased FVIII activity; P = 0.020. In those women with FVIII gt 1.5 IU/ml, who were carriers of prothrombotic mutations, an OR of 3.76 (CI 95% 1.276-11.096; P = 0.016) was obtained for VTE. Conclusion: The results of our study showed that the factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen.", publisher = "Elsevier, Amsterdam", journal = "European Journal of Internal Medicine", title = "Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study", pages = "67-63", number = "1", volume = "26", doi = "10.1016/j.ejim.2014.12.015" }
Kovač, M., Kovac, Z., Tomasević, Z., Vucicević, S., Đorđević, V., Pruner, I.,& Radojković, D.. (2015). Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study. in European Journal of Internal Medicine Elsevier, Amsterdam., 26(1), 63-67. https://doi.org/10.1016/j.ejim.2014.12.015
Kovač M, Kovac Z, Tomasević Z, Vucicević S, Đorđević V, Pruner I, Radojković D. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study. in European Journal of Internal Medicine. 2015;26(1):63-67. doi:10.1016/j.ejim.2014.12.015 .
Kovač, Mirjana, Kovac, Zeljko, Tomasević, Zorica, Vucicević, Slavko, Đorđević, Valentina, Pruner, Iva, Radojković, Dragica, "Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study" in European Journal of Internal Medicine, 26, no. 1 (2015):63-67, https://doi.org/10.1016/j.ejim.2014.12.015 . .